Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Taladegib |
Synonyms | |
Therapy Description |
Taladegib (LY-2940680) inhibits Smo, thereby inhibiting Hedgehog signaling and subsequent cell proliferation (Cancer Res 2011;71(8 Suppl):Abstract nr 2819, PMID: 29483143, PMID: 29453627). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Taladegib | LY2940680|LY-2940680|ENV-101 | SMO Inhibitor 16 | Taladegib (LY-2940680) inhibits Smo, thereby inhibiting Hedgehog signaling and subsequent cell proliferation (Cancer Res 2011;71(8 Suppl):Abstract nr 2819, PMID: 29483143, PMID: 29453627). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05199584 | Phase II | Taladegib | A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | Active, not recruiting | USA | 0 |
NCT02530437 | Phase Ib/II | Taladegib Carboplatin + Paclitaxel | A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction | Terminated | USA | 0 |
NCT01722292 | Phase Ib/II | Taladegib Carboplatin + Etoposide | A Study of LY2940680 in Small Cell Lung Cancer | Terminated | USA | GBR | 0 |